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Abstract: In previous studies, we have isolated several marine indole alkaloids and evaluated them
in the forced swim test (FST) and locomotor activity test, revealing their potential as antidepressant
and sedative drug leads. Amongst the reported metabolites to display such activities was
5-bromo-N,N-dimethyltryptamine. Owing to the importance of the judicious introduction of halogens
into drug candidates, we synthesized two series built on a 2-(1H-indol-3-yl)-N,N-dimethylethanamine
scaffold with different halogen substitutions. The synthesized compounds were evaluated for
their in vitro and in vivo antidepressant and sedative activities using the mouse forced swim and
locomotor activity tests. Receptor binding studies of these compounds to serotonin (5-HT) receptors
were conducted. Amongst the prepared compounds, 2-(1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide
(1a), 2-(5-bromo-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide (1d), 2-(1H-indol-3-yl)-N,N
-dimethylethanamine
(2a),
2-(5-chloro-1H-indol-3-yl)-N,
N-dimethylethanamine
(2c),
2-(5-bromo-1H-indol-3-yl)-N,N-dimethylethanamine (2d), and 2-(5-iodo-1H-indol-3-yl)-N,N
-dimethylethanamine (2e) have been shown to possess significant antidepressant-like action, while
compounds 2c, 2d, and 2e exhibited potent sedative activity. Compounds 2a, 2c, 2d, and 2e showed
nanomolar affinities to serotonin receptors 5-HT1A and 5-HT7 . The in vitro data indicates that the
antidepressant action exerted by these compounds in vivo is mediated, at least in part, via interaction
with serotonin receptors. The data presented here shows the valuable role that bromine plays in
providing novel chemical space and electrostatic interactions. Bromine is ubiquitous in the marine
environment and a common element of marine natural products.
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1. Introduction
Depression is the most common neuropsychiatric disorder affecting approximately 7% of
Americans each year [1]. According to the National Institute of Mental Health (NIMH), every
year about 40 million American adults suffer from anxiety disorders that frequently co-occur with
other psychiatric illnesses, like depression [2]. Both disorders are often treated with antidepressant
medications. All currently available antidepressant drugs primarily enhance the monoaminergic
transmitter system by either inhibiting the catabolism or reuptake of monoamine neurotransmitters
(serotonin, norepinephrine, or dopamine) thus elevating their brain levels. Unfortunately, clinically
used antidepressants suffer from major drawbacks, including unfavorable adverse effects that range
from weight gain to sexual dysfunction and a therapeutic lag of 4–8 weeks before a clinically relevant
therapeutic effect is discernible. Anxiety disorders can also be treated with sedative medications,
which have the added problem of potential abuse/addiction, and other adverse effects like drowsiness,
dizziness, and headaches. Accordingly, there is a clear need for more effective and safer drugs for
depression and anxiety disorders. Recently various marine natural products have been reported
as valuable drug leads for neurological disorders and here we illustrate the unique activity of
brominated molecules supporting the value of brominated marine natural products in the selectivity
for neurological receptors and other target proteins [3–5].
In our recent chemical review of marine indole alkaloids as potential new drug leads for the control
of depression and anxiety, we have seen the growing number of reported indole alkaloids and
increased brominated functionality from various marine organisms. Many marine alkaloids are
halogenated due to the presence of haloperoxidase enzymes in the marine environment. The structural
similarity of endogenous amine neurotransmitters and indole alkaloids has led researchers to
explore the neurological activity of such molecules [5–11]. Compounds like 6-bromoaplysinopsin,
N-30 -ethylaplysinopsin, and 6-bromo-20 -de-N-methylaplysinopsin, isolated from Smenospongia aurea,
were reported to display high-affinity antagonist binding for 5-HT2C and 5-HT2A serotonin receptors.
N-30 -ethylaplysinopsin did not display selectivity to either of these two receptors; however,
6-bromo-20 -de-N-methylaplysinopsin exhibited ~40-fold selectivity to 5-HT2C receptors [5].
A significant number of drugs and drug candidates in clinical trials are halogenated.
It is noteworthy that 50% of the top leading drugs on the market are halogenated, and halogens
survive throughout the drug development process, from initial discovery to launch [12]. Halogens are
included in rational drug design strategies primarily to enhance membrane permeability [13], fill spaces
in the binding pocket, and decrease metabolic degradation. They can improve potency and impact
target selectivity by affecting pKa and by changing conformation, lipophilicity, and hydrophobic
interactions especially in hydrophobic pockets such those of serotonin receptors 5-HT1A and 5-HT7
(Figure 1).
It is highly important to declare that halogens not only play the traditional role as H-bond
acceptors, they are also endowed with establishing another intermolecular bond. This newly
recognized and highly appreciated bond was recently defined as the halogen bond (X-bond)
(Figure 2) [14,15] that has an emerging role in biomolecular systems. Halogen anisotropic distribution
of the electron density forms a small positive electrostatic potential cap that is named the sigma
hole [16,17]. Due to its exceptionally high electronegativity, fluorine is normally unable to serve as an
X-bond donor, unlike other halogens. We considered fluorine incorporation into our derivatives due to
its emerging application in positron emission tomography (PET) which enhances its utility for central
nervous system (CNS) drug discovery. This is attributed to the favorable 18 F half-life (109.8 min) when
compared to 13 C (20.4 min) and 124 I (4.2 days) [18–20]. Taken together, we considered the incorporation
of different halogen atoms in our design.
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Receptor
5-HT1A
5-HT1B
5-HT1D
5-HT1E
Receptor
5-HT2B
5-HT3
5-HT5A1A
5-HT
5-HT61B
5-HT
5-HT71D
5-HT
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Controls
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Methysergide
Ki (nM)
Ki (nM)
Table
Binding affinities
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9.6 ± 1.1compounds
130.0towards
± 16.0
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0.3
Controls 69.0
Compound
2a 356.0
Compound
Compound
Compound
>10,000
± 34.0 2c
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± 30.0
310.0 ± 33.0 2e
19.0
237.0
Ergotamine
Methysergide
Ki± (nM)
(nM)
2d Ki
(nM)
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dose range. Compound 1a showed significant antidepressant-like action only at the 20 mg/kg dose
(p < 0.01) and a significant increase in locomotor activity at the 40 mg/kg dose (p < 0.01). Compound 2c
Full dose response studies for effects in FST as well as locomotor activity were conducted for
showed a significant reduction in immobility time at the 10 (p < 0.01) and 20 (p < 0.001) mg/kg doses
compounds 1a, 1d, 2a, 2c, 2d, and 2e (Figure 4a,b). Results revealed that, with the exception of
and significant decrease in locomotor activity at both the 20 and 40 mg/kg doses (p < 0.01).
compound 2d, all the tested compounds show a U-shaped dose response effect in the FST, at the tested
Similarly, compound 2e had significant antidepressant-like effect in the FST at 10 and 20 mg/kg
dose range. Compound 1a showed significant antidepressant-like action only at the 20 mg/kg dose
(p < 0.001) that coincided with a significant hypolocomotive effect (p < 0.05 at 10 mg/kg and p < 0.01 at
(p < 0.01) and a significant increase in locomotor activity at the 40 mg/kg dose (p < 0.01). Compound
20 mg/kg). Compound 2d, which did not show an antidepressant-like action in the initial evaluation
2c showed a significant reduction in immobility time at the 10 (p < 0.01) and 20 (p < 0.001) mg/kg
studies, exerted a significant reduction in immobility at 40 mg/kg (p < 0.001) accompanied by a
doses and significant decrease in locomotor activity at both the 20 and 40 mg/kg doses (p < 0.01).
significant decrease in locomotor activity at the same dose (p < 0.01).
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Similarly, compound 2e had significant antidepressant-like effect in the FST at 10 and 20 mg/kg
(p < 0.001) that coincided with a significant hypolocomotive effect (p < 0.05 at 10 mg/kg and p < 0.01 at
20 mg/kg). Compound 2d, which did not show an antidepressant-like action in the initial evaluation
studies, exerted a significant reduction in immobility at 40 mg/kg (p < 0.001) accompanied by
a significant decrease in locomotor activity at the same dose (p < 0.01).
As shown in Table 2, the tricyclic antidepressant desipramine, the selective serotonin reuptake
inhibitor fluoxetine, and the dual dopamine and noradrenaline inhibitor bupropion, all showed dose
dependent reduction in immobility times in the FST. Such effects have been previously established as a
measure of antidepressant-like action. Both desipramine and fluoxetine caused significant reduction in
locomotor activity indicative of their established sedative action. On the other hand, bupropion induced
a significant stimulant effect. These trends are consistent with previously published literature [26,27].
Table 2. Effect of control antidepressants and synthesized compounds on immobility time in mouse
forced swim test and total locomotor activity.
Treatment

Immobility (sec)

Locomotor

Vehicle
Bupropion 10 mg/kg
Bupropion 20 mg/kg
Bupropion 40 mg/kg
Fluoxetine 10 mg/kg
Fluoxetine 20 mg/kg
Fluoxetine 40 mg/kg
Desipramine 10 mg/kg
Desipramine 20 mg/kg
Desipramine 40 mg/kg
Compound 1a 10 mg/kg
Compound 1a 20 mg/kg
Compound 1a 40 mg/kg
Compound 1d 10 mg/kg
Compound 1d 20 mg/kg
Compound 1d 40 mg/kg
Compound 2a 10 mg/kg
Compound 2a 20 mg/kg
Compound 2a 40 mg/kg
Compound 2c 10 mg/kg
Compound 2c 20 mg/kg
Compound 2c 40 mg/kg
Compound 2d 10 mg/kg
Compound 2d 20 mg/kg
Compound 2d 40 mg/kg
Compound 2e 10 mg/kg
Compound 2e 20 mg/kg
Compound 2e 40 mg/kg

121 ± 7.3
101 ± 10.5
80 ± 7.1 **
58 ± 8.2 ***
91 ± 10
90 ± 6.8
75.8 ± 12.9 **
112 ± 6.6
81 ± 4.9 **
70 ± 8.9 ***
84.3 ± 6.3
70.4 ± 7.8 **
89.1 ± 7.6
106.9 ± 7.5
81.8 ± 7.5
66 ± 12.4 *
114.3 ± 9.2
55.7 ± 4.6 **
95.7 ± 8.2
63.4 ± 9.3 **
71.6 ± 11.7 **
84.6 ± 11.5
103 ± 8.9
110.8 ± 7.5
52.4 ± 11.1 ***
51.6 ± 12.8 ***
62.1 ± 2.6 ***
91.6 ± 4.9

1618 ± 142
2746 ± 298 *
3564 ± 503 ***
5290 ± 544 ***
1898 ± 132
1293 ± 243
143 ± 34 ***
763 ± 112 **
776 ± 265 **
117 ± 43 ***
1717 ± 221
958.6 ± 279
1945 ± 195 **
1348 ± 159
812 ± 258
1233 ± 286
764 ± 155
549 ± 111
1036 ± 93
956 ± 171
275 ± 96 **
92 ± 38 **
1141 ± 317
521 ± 95
73 ± 34 **
296 ± 139*
227 ± 59 **
729 ± 119

* p < 0.05, ** p < 0.01, *** p < 0.001 (Dunnett’s post-hoc test versus vehicle).

Compound 1a exhibited significant (p < 0.05) antidepressant-like activity in the FST at the
20 mg/kg dose (Figure 4a). Similarly, compound 1d caused significant (p < 0.05) reduction in
immobility indicative of antidepressant action, but at the higher 40 mg/kg dose. Furthermore, such
effect was not associated with any effect on the locomotor activity of the animals as shown in Figure 4b.
Such data indicate possible antidepressant action for both compounds without potential sedative effect
at the tested dose. Figure 4b shows the effect of compounds 2a–e in the FST and on the locomotor
activity of animals in an open field.
Compound 2a; N,N-dimethyltryptamine (DMT) is a known hallucinogen found in psychoactive
snuffs and teas used by native shamans of South America. DMT is also produced in mammalian
organisms and it was recently reported to be an endogenous sigma receptor ligand [8]. In our study,
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compound 2a caused significant reduction in immobility (p < 0.01) in the FST and a non-significant
reduction in locomotor activity. The compound did not cause any locomotor stimulant action, usually
associated with hallucinogenic effects, at any of the tested doses. Compounds 2c and 2e exhibited
significant antidepressant-like action in the FST (p < 0.01, and p < 0.001, respectively) at the 20 mg/kg
dose. In addition, compounds 2b, 2c, and 2e caused significant reduction in locomotor activity
suggesting a potential sedative effect. Compound 2b did not show any antidepressant action in the
initial evaluation, but the sedative effect was highly pronounced, thus, it was further pursued in the
molecular modeling study. Such studies will help direct further research regarding the observed
sedative action for this compound.
Full dose response studies for compound 1a elicited a U-shaped dose response antidepressant-like
action (Figure 4a) with the 20 mg/kg dose significantly different from the vehicle control (p < 0.01).
A similar U-shaped response was observed in locomotor activity with a significant stimulant action
evident at the 40 mg/kg dose (p < 0.01). All tested compounds, except compound 1d, exhibited
similar U-shaped antidepressant-like dose response curves (Figure 4a). In some cases, the lack of
antidepressant action at the high dose can be partially explained by the severe sedative action observed
in the locomotor activity (compound 2c, Figure 4b). Such severe sedation can mask the antidepressant
action by hindering the animal’s ability to escape or move. Further studies are needed to examine
the potential sedative action of this compound. In other cases (compounds 2a and 2e), the trend
of effect on locomotor activity does not correlate with the lack of antidepressant action (Figure 4b).
The observed U-shaped dose response could possibly be attributed to activation of a separate set of
pathways through the action on multiple receptors at the high dose. Thus, mechanistic studies are
warranted to delineate the mechanisms underlying the observed antidepressant and sedative actions
for these compounds. On the other hand, compound 1d showed a dose-dependent response curve
with significant antidepressant-like action at the 40 mg/kg dose (p < 0.01) and no significant effect on
locomotor activity (Figure 4b).
2.3. Assessment of the Docking with 5-HT7 , and 5-HT1A
Using the human β2 -adrenergic G protein-coupled receptor as a template, two homology models
of 5-HT1A and 5-HT7 were generated. Throughout our molecular modelling studies, we focused
primarily on compounds 2a–e that have a protonated amino group as a crucial common feature for
interacting with the key amino acids Asp116 and Asp162 of 5-HT1A and 5-HT7 models, respectively [12].
Regarding 5-HT1A , docking result of compound 2a revealed its ability to form a salt bridge between its
protonated dimethyl amino group and Asp116 carboxylate. Its indole hydrophobic surface is buried
into the hydrophobic pocket making edge to face stacking with Tyr195 and forming an arene-H
interaction with Phe361 (Figure 5a). The remaining compounds with a halogen substitution have
various binding modes that can explain the affinity variations. Binding of compound 2b with 5-HT1A
is somewhat more favorable than 2a in spite of having a very similar mode (Figure 5a). Fluorine is a
small atom with a van der Waals radius of 1.47 Å, slightly more than the value for hydrogen at 1.20 Å,
that increases the possibility of van der Waals interactions. Moreover, the fluorine inductive effect
increases the polarizability of neighboring hydrogens and the N-H bond on the indole moiety [28].
On the other hand, compounds 2c and 2d have reoriented to adopt the same binding conformation
forming an X-bond through their chloride and bromide substitutions with Ala93, as anticipated, and
two H-bonds with Asp116 and Asn386 (Figure 5b). Although 2e is bound to Ala93 via an X-bond
in the same manner, unlike 2c and 2d, it did not form an H-bond with Asn386. Therefore, 2e is less
anchored in the pocket leading to less affinity towards 5-HT1A (Figure 5c).

Mar. Drugs 2017, 15, 248

8 of 14

Mar. Drugs 2017, 15, 248

8 of 14

Figure 5. Docking interactions of compounds 2a–e into 5-HT1A model binding site. (a) Superimposed
Figure 5. Docking interactions of compounds 2a–e into 5-HT1A model binding site. (a) Superimposed
structures of 2a (green) and 2b (red). (b) Superimposed structures of 2c (red) and 2d (green).
structures of 2a (green) and 2b (red). (b) Superimposed structures of 2c (red) and 2d (green).
(c) Compound 2e (green). Key binding site residues are rendered as cyan stick models.
(c) Compound 2e (green). Key binding site residues are rendered as cyan stick models.
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Figure 6. Docking interactions of compounds 2a–e into 5-HT7 model binding site. (a) Superimposed
Figure 6. Docking interactions of compounds 2a–e into 5-HT7 model binding site. (a) Superimposed
structures of 2a (green), 2b (yellow), and 2e (green). (b) Superimposed structures of 2c (red) and
structures of 2a (green), 2b (yellow), and 2e (green). (b) Superimposed structures of 2c (red) and
2d (green).
2d (green).
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Table 3. Lipinski properties of compounds 2a–e.
Table 3. Lipinski properties of compounds 2a–e.
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Log p
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1
1
3
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regulations of the National Institutes of Health Guide for Care and Use of Laboratory Animals
3.2. Synthesis of Targeted Molecules
(Protocol number 07-017).
3.2.1. The 2-(1H-Indol-3-yl)-N,N-dimethylethanamine (2a)
3.2. Synthesis of Targeted Molecules
C12H16N2, was purified as a brownish white precipitate, 1H NMR (MeOD): δ = 1.61 (s, 6H), 1.99
3.2.1.
The 2.35
2-(1H-Indol-3-yl)-N,N-dimethylethanamine
(d, 2H),
(d, 2H), 6.41 (s, 1H), 6.56 (dt, 1H), 6.85 (d, (2a)
1H), 7.06 (d, 1H),13C NMR (MeOD) δ24.11 (t),
45.66
(t), 112.39
(d),as113.54
(s), 119.34
(s),precipitate,
119.68 (d), 122.40
(d), (MeOD):
123.10 (d),δ 128.64
137.97
1 H NMR
C12(q),
H1661.01
N2 , was
purified
a brownish
white
= 1.61 (s),
(s, 6H),
1.99
(s),
(Supporting
Information).
13
(d, 2H), 2.35 (d, 2H), 6.41 (s, 1H), 6.56 (dt, 1H), 6.85 (d, 1H), 7.06 (d, 1H), C NMR (MeOD) δ24.11 (t),

45.66 (q), 61.01 (t), 112.39 (d), 113.54 (s), 119.34 (s), 119.68 (d), 122.40 (d), 123.10 (d), 128.64 (s), 137.97 (s),
(Supporting Information).
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3.2.2. The 2-(5-Floro-1H-indol-3-yl)-N,N-dimethylethanamine (2b)
C12 H15 N2 F, was purified as a yellowish white precipitate, 1 H NMR (MeOD), 1 H NMR δ1.79
(s, 6H), 2.97 (d, 2H), 3.12 (d, 2H), 6.74 (dt, 1H), 7.08 (s, 1H), 7.15 (m, 2H). 13 C NMR (MeOD) δ22.01 (t),
43.64 (q), 59.15 (t), 103.76 (d), 104.00 (s), 110.83 (s), 111.10 (d), 113.44 (d), 113.54 (d), 126.16 (s), 134.86 (s),
(Supporting Information).
3.2.3. The 2-(5-Chloro-1H-indol-3-yl)-N,N-dimethylethanamine (2c)
C12 H15 N2 Cl, was purified as a yellowish white precipitate, 1 H NMR (MeOD), 1 H NMR δ2.36
(s, 6H), 2.70 (d, 2H), 2.91 (d, 2H), 5.93 (t, 1H), 6.99 (s, 1H), 7.24 (d, 1H), 7.47(s, 1H). 13 C NMR (MeOD)
δ22.48 (t), 43.67 (q), 59.67 (t), 110.83 (d), 111.60 (s), 117.69 (s), 118.21 (d), 120.96 (d), 121.83 (d), 127.15 (s),
136.79 (s), (Supporting Information).
3.2.4. The 2-(5-Bromo-1H-indol-3-yl)-N,N-dimethylethanamine (2d)
C12 H15 N2 Br, was purified as a yellowish white precipitate, 1 H NMR (MeOD), 1 H NMR δ2.191
(s, 6H), 2.48 (d, 2H), 2.75 (d, 2H), 6.95 (s, 1H), 7.07 (d, 1H), 7.130 (d, 1H), 7.56 (s, 1H). 13 C NMR (MeOD)
δ24.11 (t), 45.46 (q), 61.39 (t), 112.88 (d), 113.57 (s), 114.05 (s), 121.88 (d), 124.86 (d), 125.14 (d), 130.59 (s),
136.84 (s), (Supporting Information).
3.2.5. The 2-(5-Iodo-1H-indol-3-yl)-N,N-dimethylethanamine (2e)
C12 H15 N2 I, was purified as a yellowish white precipitate, 1 H NMR (MeOD), 1 H NMR δ2.21
(s, 6H), 2.53 (d, 2H), 2.82 (d, 2H), 6.93 (s, 1H), 6.99 (t, 1H), 7.22 (d, 1H), 7.42 (d, 1H). 13 C NMR (MeOD)
δ24.29 (t), 46.0 (q), 61.80 (t), 112.41 (d), 113.66 (s), 119.30 (s), 119.77 (d), 122.42 (d), 123.22 (d), 128.75 (s),
138.25 (s), (Supporting Information).
3.3. In Vitro Binding to Serotonin Receptors
Compounds 2a, 2c, 2d, and 2e were tested in the NIMH Psychoactive Drug Screening Program
(University of North Carolina, Chapel Hill, NC, USA) in a panel of cloned human and rodent receptors,
channels, and transporters (Table 1). For more experimental details, please refer to the Psychoactive
Drug Screening Program (PDSP) web site https://pdspdb.unc.edu/pdspWeb/.
3.4. The Forced Swim Test (FST)
The FST represents a model of behavioral despair where the mice were subjected to an inescapable
situation (in our case, the mice were placed in a cylinder of water). This model usually exhibits
behavioral despair within 2 min of a 6 min session. The antidepressant effect is elicited as a reduction
in the immobility time and continued escape attempts (swimming and climbing) [30]. Swiss Webster
mice were injected intraperitoneally (i.p.) with the examined compound, vehicle (10% ethanol), or
with control antidepressant bupropion, desipramine, or fluoxetine (10–40 mg/kg, i.p.), n = 7–10/group.
Animals were instantly placed in individual locomotor chambers where their overall activity was
recorded for 30 min. The mice were then individually placed in transparent plastic cylinders (height
23 cm, internal diameter 10 cm) filled with 8 cm of deionized water at 25 ◦ C. Each individual mouse was
videotaped for 6 min. Digital video outcome was then analyzed via SMART II Video Tracking System
Software (San Diego Instruments, San Diego, CA, USA). This software determined the immobility in the
6 min session, where the last four minutes’ data were utilized to determine the effect. The immobility
time was clarified to be the time spent by each mouse moving at a speed below 2 cm/s. This threshold
speed was chosen based on previously published data and the validation of our automated system. This
threshold generated similar immobility scores to those determined from manually scored tapes [31].
Compounds 1a–e and 2a–e were evaluated for their possible antidepressant activity in the
forced swim test [32], where the compounds were initially tested at a dose of 20 mg/kg in
comparison to the model molecules: 2-(5,6-di-bromo-1H-indol-3-yl)-N,N-dimethylethanamine and
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2-(5-bromo-1H-indol-3-yl)-N,N-dimethylethanamine derivatives which previously showed significant
antidepressant and sedative action at a similar dose. A number of clinically used antidepressants
(the selective serotonin reuptake inhibitor fluoxetine, the tricyclic antidepressant desipramine, and the
dual dopamine and norepinephrine inhibitor bupropion) were utilized as positive controls.
3.5. The Locomotor Activity Test
Coupled to the FST, the effect of the test compound on locomotor activity was monitored to avoid
any false positives resulting from stimulant action, as well as to evaluate any potential sedative action
of the compound. Locomotor activity was measured using an automated activity monitoring system
(San Diego Instruments, San Diego, CA, USA). Mice were acclimated to the testing environment for
30 min and then injected (i.p.) with vehicle (10% ethanol), control antidepressant, or the test compound.
Each mouse was immediately placed in a Plexiglas enclosure and locomotor activity monitored for the
next 30 min. Activity was recorded as interruptions of two sets of photo-beams. The data during the
last 10 min of the testing period were analyzed. Immediately following the locomotor measurements
(equivalent to the 30 min pretreatment time), the mice were subject to the FST as described above.
The effect on locomotor activity was also evaluated to eliminate a non-specific stimulating effect
and to reveal any possible sedative activity. As shown in Table 2, the control antidepressants showed
significant dose-dependent reduction in immobility consistent with their established antidepressant
action. The effect on locomotor activity was different, whereby both desipramine and fluoxetine caused
significant reduction in activity, while bupropion showed a significant locomotor stimulant effect.
3.6. Data Analysis
All measured values were documented as mean ± S.E.M. with n = 7–10 animals/group. Data were
validated using One Way ANOVA and Dunnett’s post hoc test to observe the significant difference
with respect to the vehicle control at p < 0.05.
3.7. Homology Modeling
To construct homology models of 5-HT1A and 5-HT7 receptors, the crystal structure of the seven
helix bundle of human β2 -adrenergic receptor Protein Data Bank (PDB code 2RH1) [33] was retrieved
from Brookhaven Protein Data Bank and employed as the template. Amino acid sequences of the target
receptors (P08908 for 5-HT1A and P34969 for 5-HT7 ) were downloaded from the UniProt database
(http://www.uniprot.org). The models were built by I-Tasser [34] and the valid models were selected
according to their C-score [35]. QuickPrep protocol, implemented in Molecular Operating Environment
(MOE) 2015.10, was used to assign the charge the state of ionizable residues, add hydrogens, and
perform energy minimization.
3.8. Preparation of Ligand Structures and Docking
Three dimensional structures of the active hits were sketched by the Builder module of MOE. They
were protonated, minimized, and then docked into the generated homology models using the standard
docking protocol implemented in MOE as described before [36]. Ligand conformations were placed in
the site with the Triangle Matcher method and ranked with the London dG scoring function.
4. Conclusions
Data collected show that compounds 2a, 2c, 2d, and 2e possessed high nanomolar affinity to
several serotonin receptor subtypes, particularly 5-HT1A , 5-HT1B/1D , 5-HT2B , 5-HT6 , and 5-HT7
subtypes. It has been shown that introduction of fluorine at position 6 of N,N-dimethyltryptamine
causes a 5-fold decrease in affinity toward the 5-HT1A receptor [5].
Similarly, introducing fluorine at the 6 position of 5-methoxy-N,N-dimethyltryptamine decreases
the 5-HT1A receptor binding affinity. However fluorination of 5-methoxy-N,N-dimethyltryptamine
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at position 4 increases the affinity toward the 5-HT1A receptor. Based on our data (Table 1),
the unsubstituted N,N-dimethyltryptamine (2a) shows good affinity towards 5-HT1D and
5-HT1B similar to 5-chloro-, bromo-, and 5-iodo-N,N-dimethyltryptamine (2c–e). In addition,
5-chloro-N,N-dimethyltryptamine shows strong affinity towards 5-HT1A , 5-HT2B , and 5-HT7 . While
5-bromo-N,N-dimethyltryptamine (2d) shows strong affinity towards 5-HT1A , 5-HT2B , 5-HT6 , and
5-HT7 . Previous research has suggested the involvement of these serotonin receptor subtypes in
depression, anxiety, and migraines [37].
The utilization of 5-HT1A knockout animals has resulted in enhanced anxiety in several
experimental paradigms, as well as demonstrated significant increased baseline immobility in
behavioral despair tests [38,39]. Moreover, selective 5-HT1A agonists have shown antidepressant
actions in preclinical as well as clinical testing [40–43]. The involvement of 5-HT1B receptors in mood
disorders has also been observed in knockout models. Such mice exhibited a decreased anxiety in
open field, elevated plus maze, and tail suspension tests. On the other hand, the same mice displayed
increased aggressive behavior [44,45].
Additionally, 5-HT1B and 5-HT1D receptors are well known targets for anti-migraine medications.
A number of studies have examined the role of 5-HT2B receptors in mood regulation. These studies
showed that direct injection of the selective 5-HT2B agonist, BW 723C86, into the medial amygdale
results in anxiolytic effect in the rat social interaction test [46].
The attribution of 5-HT6 and 5-HT7 receptors in neuropsychiatric disorders has recently drawn
attention due to the pharmacological studies that demonstrated high affinity of several antipsychotic
and antidepressant agents to these two receptor subtypes [47,48]. Thus, the in vitro data suggest
that the antidepressant action exerted by these compounds in vivo might be mediated via interaction
with serotonin receptors. Further mechanistic studies are hence required to delineate the nature of
such interactions and further establish the mechanism underlying the observed behavioral effects of
these compounds.
Supplementary Materials: Supplementary material to this article can be found online at www.mdpi.com/16603397/15/8/248/s1.
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